Drug intelligence / Profile preview

ETBX-011 + ALT-803

Development stage: Discontinued
Lead developer: ImmunityBio
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ETBX-011 + ALT-803 is a combination therapy under investigation for the treatment of cancers expressing carcinoembryonic antigen (CEA), including colorectal, medullary thyroid, ovarian, breast, lung, and pancreatic cancers. ETBX-011 is a recombinant viral vector cancer vaccine based on an Ad5 [E1-, E2b-]-CEA(6D) platform that delivers the CEA antigen to prime host immune responses. ALT-803, meanwhile, is an interleukin-15 (IL-15) superagonist complex (IL-15N72D:IL-15RαSu/IgG1 Fc), designed to enhance activation and proliferation of natural killer (NK) cells and CD8+ T cells. In combination, the therapy aims to boost anti-tumor immunity by both priming cancer-specific T cells (via ETBX-011) and amplifying NK and T-cell function (via ALT-803). Clinical investigation focused on patients with advanced, previously treated, CEA-expressing tumors[1][3][7].

Other names: N-803N803N 803

Targets

CXADR (Coxsackievirus and adenovirus receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on ETBX-011 + ALT-803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETBX-011 + ALT-803.

Explore the full profile